GlassScriptPhysician profile
Kenneth F Lyons
NPI 1346208600
$1,366.16
in general payments reported to CMS, 2019-2025
18 companies · $419 in 2025
The $419 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $39.53 · 2021: $80.75 · 2022: $254 · 2023: $174 · 2024: $231 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $233.01 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $203.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $200.67 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Kaleo, INC. | $117.90 | 2019-2024 | Auvi-Q |
| Corium, LLC | $112.97 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $84.60 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.91 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $59.49 | 2025 | Jornay Pm |
| Alk-Abello, INC | $52.51 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $50.18 | 2025 | |
| Sobi, INC | $43.82 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $28.53 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $24.48 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $21.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.52 | 2025 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $19.35 | 2025 | Aptima |
| Seqirus USA INC | $17.48 | 2023 | Flucelvax Quadrivalent |
| Neos Therapeutics, LP | $13.66 | 2025 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.